Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0D6KZ
|
||||
Former ID |
DNC014174
|
||||
Drug Name |
KNT-62
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [1] | ||
Structure |
![]() |
Download2D MOL |
|||
Formula |
C28H30N2O5
|
||||
Canonical SMILES |
C1CC1CN2CCC34C5C6(CCC3(C2CC7=C4C(=C(C=C7)O)O5)OC6C(=O)N<br />C8=CC=CC=C8)O
|
||||
InChI |
1S/C28H30N2O5/c31-19-9-8-17-14-20-28-11-10-27(33,23(35-28)24(32)29-18-4-2-1-3-5-18)25-26(28,21(17)22(19)34-25)12-13-30(20)15-16-6-7-16/h1-5,8-9,16,20,23,25,31,33H,6-7,10-15H2,(H,29,32)/t20-,23-,25+,26-,27-,28+/m0/s1
|
||||
InChIKey |
YYNRSCGPLWDLNI-MRMNDBNLSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Kappa-type opioid receptor | Target Info | Inhibitor | [1] | |
Mu-type opioid receptor | Target Info | Inhibitor | [1] | ||
KEGG Pathway | Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | ||||
Estrogen signaling pathway | |||||
Morphine addiction | |||||
NetPath Pathway | TCR Signaling Pathway | ||||
PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
Opioid prodynorphin pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
Enkephalin release | |||||
Pathway Interaction Database | IL4-mediated signaling events | ||||
Reactome | Peptide ligand-binding receptors | ||||
G alpha (i) signalling eventsR-HSA-375276:Peptide ligand-binding receptors | |||||
G alpha (i) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Peptide GPCRs | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP69:TCR Signaling Pathway | |||||
Opioid Signalling | |||||
GPCR downstream signaling | |||||
References | |||||
REF 1 | Bioorg Med Chem Lett. 2010 Jan 1;20(1):121-4. Epub 2009 Nov 13.Drug design and synthesis of a novel kappa opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.